mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody

This regimen is a combination therapy used primarily in oncology, especially for advanced or metastatic colorectal cancer. It consists of three components: - **mFOLFOX6** (modified FOLinic acid [leucovorin], Fluorouracil [5-FU], and OXaliplatin): a standard chemotherapy protocol that targets rapidly dividing cells by interfering with DNA synthesis and function[1][2][7]. - **Bevacizumab**: a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis to restrict tumor blood supply[3]. - **PD-1 monoclonal antibody** (such as pembrolizumab or nivolumab): an immune checkpoint inhibitor that blocks the programmed cell death protein 1 (PD-1) pathway on T-cells, enhancing the immune system's ability to recognize and destroy cancer cells[6][8][10]. The combination leverages cytotoxic chemotherapy, antiangiogenic therapy, and immunotherapy for synergistic antitumor effects.

Other names

mFOLFOX6 plus bevacizumab and PD-1 inhibitormFOLFOX-6 plus bevacizumab and PD-1 inhibitormFOLFOX 6 plus bevacizumab and PD-1 inhibitormFOLFOX6 + bevacizumab + anti-PD-1 antibody